TrialReader


PREventing CHemotherapy Induced Neuropathy (PreChIN)

NCT03299582 — Not applicable, Completed, 89 participants, National University Hospital, Singapore

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT03299582
StatusCompleted
PhaseNot applicable
Study typeInterventional; non randomized, sequential, masking: none, prevention
Enrollment89 (Actual)
SponsorNational University Hospital, Singapore (Other)
ConditionsChemotherapy-induced Peripheral Neuropathy (CIPN)
InterventionsHypothermia, Cryocompression (Device)
Datesstart 2013-06-13, primary completion 2016-11-03, completion 2017-02-15, first posted 2017-10-03, last updated 2017-10-03

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Chemotherapy-induced Peripheral Neuropathy (CIPN) All trials of Hypothermia All trials of Cryocompression

-Summary

The project is designed to study the use of localized hypothermia alone, or with compression to the limbs during chemotherapy infusion for the prevention of chemotherapy induced peripheral neuropathy (CIPN). As a pilot study, safety, tolerability and early clinical activity will be studied. The study will be conducted on healthy volunteers and cancer patients receiving taxane chemotherapy.

Expand all sections  ·  Collapse all

+Detailed description

Localized limb hypothermia during chemotherapeutic infusion may prevent a common side effect of chemotherapy: chemotherapy-induced peripheral neuropathy (CIPN). There are no reliable methods for the prevention or the treatment of CIPN. On the basis of the dose-related pathophysiology of CIPN, the investigators hypothesize that reducing the delivery of the toxic chemotherapeutic agents to the peripheral nerves by reducing blood flow through hypothermia may reduce the occurrence of CIPN. The proposed potential treatment method would aim to reduce the development of CIPN. This project comprises of a healthy subject trial to investigate the best tolerated temperature which will be used in cancer subject trial to investigate the safety and tolerability of hypothermia or cryocompression (hypothermia with pressure) in the prevention of CIPN in cancer subjects undergoing taxane-based chemotherapy.

+Arms and interventions

ArmTypeInterventionsDescription
Healthy subjects (Hypothermia)ExperimentalDevice: HypothermiaTo investigate the safety and tolerability of limb hypothermia in subjects without cancer
Healthy subjects (Cryocompresion)ExperimentalDevice: CryocompressionTo investigate the safety and tolerability of cryocompression in subjects without cancer
Cancer subjects (Hypothermia)ExperimentalDevice: HypothermiaTo investigate the safety and tolerability of limb hypothermia in subjects with breast cancer being treated with paclitaxel chemotherapy.
Cancer subjects (Cryocompresion)ExperimentalDevice: CryocompressionTo investigate the safety and tolerability of cryocompression in subjects with cancer being treated with taxane-based chemotherapy.
  • Hypothermia (Device): Healthy subjects will undergo 3 hours of hypothermia at various temperature levels.Cancer subjects will undergo 4 hours of hypothermia during every cycle of chemotherapy.
  • Cryocompression (Device): Healthy subjects will undergo 3 hours of cryocompression. Cancer subjects will undergo a minimum duration of 2 hours and a maximum duration of up to 4 hours of cryocompression during every cycle of chemotherapy.

+Outcome measures

Primary outcomes

  • Number of healthy subjects with treatment-related intolerance as assessed by CTCAE v4.0 and tolerability scales undergoing limb hypothermia or cryocompression [From the start of assessment until study completion, an average of 3 years]
  • Number of cancer patients with treatment-related intolerance as assessed by CTCAE v4.0 and tolerability scales undergoing limb hypothermia or cryocompression [From the start of assessment until study completion, an average of 3 years]

+Eligibility

Sex: All, ages: 21 Years to 80 Years, accepts healthy volunteers

The inclusion criterion for the healthy subjects

* Age 21-80 years
* Signed informed consent from patient
* No history of neuropathy
* ECOG 0
* No history of hospitalization in the past 6 months

The inclusion criteria for the cancer patients undergoing taxane-based chemotherapy

* Age 21- 80 years.
* Signed informed consent from patient or legal representative.
* Scheduled to receive taxane-based chemotherapy

The exclusion criteria for both healthy subjects and cancer patients

* Open skin wound or ulcers of the limbs
* A score of more than 5 in the Total Neuropathy Score (TNS) at baseline (Not applicable for healthy subjects)
* History of Raynaud's phenomenon, peripheral vascular disease, or poorly controlled diabetes

+Publications

  • Tomchuk D, Rubley MD, Holcomb WR, Guadagnoli M, Tarno JM. The magnitude of tissue cooling during cryotherapy with varied types of compression. J Athl Train. 2010 May-Jun;45(3):230-7. doi: 10.4085/1062-6050-45.3.230. PMID 20446835
  • Murgier J, Cassard X. Cryotherapy with dynamic intermittent compression for analgesia after anterior cruciate ligament reconstruction. Preliminary study. Orthop Traumatol Surg Res. 2014 May;100(3):309-12. doi: 10.1016/j.otsr.2013.12.019. Epub 2014 Mar 25. PMID 24679367

+Investigators

  • Amanda Chan, Principal investigator, National University Hospital, Singapore

My Notes